|Bid||83.89 x 1000|
|Ask||84.02 x 1000|
|Day's Range||83.89 - 84.93|
|52 Week Range||77.50 - 125.86|
|Beta (3Y Monthly)||1.79|
|PE Ratio (TTM)||17.64|
|Earnings Date||Jan 24, 2019 - Jan 28, 2019|
|Forward Dividend & Yield||4.28 (5.00%)|
|1y Target Est||100.33|
The Dow Jones Industrial Average gained 0.35 percent to close at 23,675.64, while the S&P 500 Index increased 0.01 percent to close at 2,546.16. The Nasdaq Composite Index climbed 0.45 percent to close at 6,783.91.
On December 14, Pfizer (PFE) announced a dividend of $0.36 for the first quarter of fiscal 2019. Pfizer announced that the dividend would be payable to shareholders on record at the close of the market on February 1. Pfizer’s dividend of $0.36 is 6% higher than the previous dividend of $0.34.
Eli Lilly's (LLY) Taltz displays superiority over standard of care medicine Humira in a head-to-head study on patients with active psoriatic arthritis.
NORTH CHICAGO, Ill. , Dec. 17, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced a new Executive Leadership Team structure designed to streamline ...
Eli Lilly and Co said on Monday its psoriatic arthritis drug, Taltz, was found to be more effective than the world's best-selling prescription medicine, AbbVie Inc's Humira, in a late-stage trial. The trial was the first of its kind to test Taltz and the standard-of-care, Humira, head-to-head in patients with active psoriatic arthritis, a form of arthritis that affects some people who have psoriasis. The study showed Taltz was as effective as Humira in improving the symptoms of psoriatic arthritis, as measured by achieving a reduction in disease activity of at least 50 percent, compared with patients that showed such results on Humira after 24 weeks.
Short interest is extremely low for ABBV with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ABBV. Over the last month, ETFs holding ABBV are favorable, with net inflows of $11.60 billion.
Shares in a handful of U.S. companies have rallied following recent announcements of increased share repurchases, a welcome development for investors bruised by market volatility. Facebook Inc., Mastercard Inc., Lowe’s Cos., AbbVie Inc., United Rentals Inc. and Pioneer Natural Resources Co. are among the companies that have unveiled bigger or resumed share buybacks this month as the S&P 500 heads toward its worst quarter since 2011. Buybacks make corporate profits appear stronger by lowering the number of shares outstanding, buoying per-share earnings even without overall profit growth.
AbbVie Inc. (ABBV) informed the market Thursday that the board of directors of the company has authorized an increase to its $10 billion stock repurchase program, which was announced this year on Feb. 15, up to $15 billion. The market should have reacted positively on Thursday but instead it answered with a 1% dip in the share price to $87.71. Warning! GuruFocus has detected 2 Warning Sign with ABBV.
NORTH CHICAGO, Ill., Dec. 13, 2018 /PRNewswire/ -- The board of directors of AbbVie Inc. (ABBV) has authorized a $5 billion increase to AbbVie's existing stock repurchase program. The stock repurchase authorization permits shares to be repurchased in open market or private transactions, has no time limit and may be discontinued at any time. AbbVie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions.
The pharmaceutical sector delivers two benefits that appeal to investors: reasonable P/E ratios and growth catalysts. Many pharma stocks have suffered as of late. Some have key drugs facing patent expirations.
AbbVie (ABBV) is a repeat recommendation because of its attractive dividend, combined with its strong growth, observes Ben Reynolds, growth & income expert and editor of Sure Retirement.
AbbVie (ABBV) reported global HCV (hepatitis C) franchise sales worth $862 million in the third quarter, a YoY (year-over-year) rise of more than 100% on both an operational and a reported basis. The company reported HCV sales of $444 million in the US market, a YoY rise of more than 100%. AbbVie also reported HCV sales of $418 million in international markets in the third quarter, YoY rises of 94.5% on a reported basis and 95.6% on an operational basis.
There's a lot of talk about Wall Street's top-rated stocks. As 2018 ends and 2019 nears, everyone - including us - is talking about our favorite stock picks for 2019, or even the next decade. But not every stock is a well-loved lunker. There are numerous stocks with bearish, or at least increasingly bearish, Wall Street sentiment. Stocks where you should look before you leap. And with the market in such a precarious state right now, it makes even more sense to pay attention to those companies that are facing significant challenges ahead. Here we used TipRanks market data to pinpoint the Street's worst-rated stocks right now. We scanned a database of more than 5,000 stocks to find the following picks - some of which represent stocks to sell, and others of which you may want to hold if you own, but certainly don't want to chase. All stocks, bar one, have an analyst consensus of "Hold" or "Sell." There's one exception, but as you'll see, sentiment is quickly turning against it too. SEE ALSO: 10 Stocks Warren Buffett Is Buying (And 6 He's Selling)
Bristol-Myers (BMY) enters into a collaboration agreement with Vedanta Biosciences to study Opdivo clubbed with the latter's VE800 for treating patients with advanced or metastatic cancers.
AbbVie (ABBV) reported global Venclexta sales worth $96 million in the third quarter, a YoY (year-over-year) rise of more than 100% on both an operational and a reported basis. As per the company’s third-quarter earnings conference call, this performance was mainly attributable to the FDA’s approval of the drug in a broader R/R (relapsed/refractory) CLL (chronic lymphocytic leukemia) indication. The company reported Venclexta sales worth $69 million in the US market, a YoY rise of more than 100%.
AbbVie (ABBV) reported global Imbruvica sales worth $972 million in the third quarter, YoY (year-over-year) rises of 41.3% on a reported basis and 41.3% on an operational basis. As per the company’s third-quarter earnings conference call, this performance was mainly attributable to robust demand for the drug across all lines of therapy in CLL (chronic lymphocytic leukemia) indications. The company reported Imbruvica sales worth $812 million in the US market, a YoY rise of 41.5%.
AbbVie (ABBV) reported global Humira sales worth $5.12 billion in the third quarter, YoY (year-over-year) rises of 9.0% on a reported basis and 9.8% on an operational basis. The company reported Humira sales of $3.55 billion in the US market, a YoY rise of 12.5%. In the first nine months of 2018, Humira reported global sales worth $15.02 billion, a YoY rise of 11.0% on a reported basis and 9.5% on an operational basis.
In a turbulent year for Gilead Sciences (NASDAQ:GILD), the company recently generated headlines that will hopefully turn things around for GILD stock. Over the weekend, insider information pegged Roche Holdings (OTCMKTS:RHHBY) executive Daniel O’Day as its new CEO. O’Day is no stranger to the industry, having served as Roche Pharmaceuticals’ chief executive since June 3, 2016.
Yes, there was a strong rebound off the October lows, which is classic market action. Almost textbook as well is the dramatic intra-day swings and alternating days of declines and advances, explains dividend specialist and value investing expert, Kelley Wright, editor of IQ Trends.
AbbVie (ABBV) expects Humira to report revenue of close to $6.3 billion in international markets in 2018. AbbVie reported Humira sales worth $1.58 billion in international markets in the third quarter, YoY (year-over-year) rises of 1.8% on a reported basis and 4.2% on an operational basis.